Overview

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Status:
RECRUITING
Trial end date:
2031-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.
Phase:
PHASE1
Details
Lead Sponsor:
Debiopharm International SA